NAT10 exacerbates acute renal inflammation by enhancing N4-acetylcytidine modification of the CCL2/CXCL1 axis
Proceedings of the National Academy of Sciences · 29.04.2025 · 122 (17)
DOI: 10.1073/pnas.2418409122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 22.04.2025. Verfasst von Jia-Nan Wang und 26 weiteren Autor:innen. Beteiligte Einrichtung: Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, The Key Laboratory of Anti-Inflammatory of Immune Medicines, Ministry of Educ…. Hauptthemen laut MEDLINE: Chemokine CXCL1, Acute Kidney Injury, Chemokine CCL2, Inflammation. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The National natural Science Foundation of China, The Nature Science Research Project of Anhui Province.
Abstract (Originalsprache)
Inflammation plays an essential role in eliminating microbial pathogens and repairing tissues, while sustained inflammation accelerates kidney damage and disease progression. Therefore, understanding the mechanisms of the inflammatory response is vital for developing therapies for inflammatory kidney diseases like acute kidney injury (AKI), which currently lacks effective treatment. Here, we identified N-acetyltransferase 10 ( NAT10 ) as an important regulator for acute inflammation. NAT10 , the only known “writer” protein for N4-acetylcytidine (ac4C) acetylation, is elevated in renal tubules across various AKI models, human biopsies, and cultured tubular epithelial cells (TECs). Conditional knockout (cKO) of NAT10 in mouse kidneys attenuates renal dysfunction, inflammation, and infiltration of macrophages and neutrophils, whereas its conditional knock-in (cKI) exacerbates these effects. Mechanistically, our findings from ac4C-RIP-seq and RNA-seq analyses revealed that NAT10-mediated ac4C acetylation enhances the mRNA stability of a range of key chemokines, including C-C motif chemokine ligand 2 ( CCL2 ) and C-X-C motif chemokine ligand 1( CXCL1 ), promoting macrophage and neutrophil recruitment and accelerating renal inflammation. Additionally, CCL2 and CXCL1 neutralizing antibodies or their receptor inhibitors, abrogated renal inflammation in NAT10 -overexpression TECs or NAT10 -cKI mice. Importantly, inhibiting NAT10 , either through Adeno-associated virus 9 (AAV9)-mediated silencing or pharmacologically with our found inhibitor Cpd-155, significantly reduces renal inflammation and injury. Thus, targeting the NAT10/CCL2/CXCL1 axis presents a promising therapeutic strategy for treating inflammatory kidney diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, The Key Laboratory of Anti-Inflammatory of Immune Medicines, Ministry of Education, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui…
- School of Basic Medicine, Anhui Medical University, Hefei 230032, China.
- Department of Pharmacy, Lu'an Hospital of Anhui Medical University, Lu'an People's Hospital of Anhui Province, Lu'an 237006, China.
- Department of Nephrology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, Anhui, China.
- School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong 999077, Hong Kong.
- Department of Chinese Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen 518000, China.
ORCID-Profile: Jia-Nan Wang, Ju-Tao Yu, Xin-Ran Cheng, Sai Zhu, Xiao-Ming Meng
Förderung
- The National natural Science Foundation of China
- The Nature Science Research Project of Anhui Province
Zitieren
APA
Wang, J. N., Suo, X. G., Yu, J. T., Luo, Q. C., Ji, M. L., Zhang, M. M., Zhu, Q., Cheng, X. R., Hou, C., Chen, X., Wang, F., Xu, C. H., Li, C., Xie, S. S., Wei, J., Zhang, D. F., Zhang, X. R., Wang, Z. J., Dong, Y. H., …, & Meng, X. M. (2025). NAT10 exacerbates acute renal inflammation by enhancing N4-acetylcytidine modification of the CCL2/CXCL1 axis. Proceedings of the National Academy of Sciences, 122(17). https://doi.org/10.1073/pnas.2418409122
Vancouver
Wang JN, Suo XG, Yu JT, Luo QC, Ji ML, Zhang MM, et al. NAT10 exacerbates acute renal inflammation by enhancing N4-acetylcytidine modification of the CCL2/CXCL1 axis. Proceedings of the National Academy of Sciences. 2025;122(17). doi:10.1073/pnas.2418409122
BibTeX
@article{Wang2025,
author = {Wang, Jia-Nan and Suo, Xiao-Guo and Yu, Ju-Tao and Luo, Qi-Chao and Ji, Ming-Lu and Zhang, Meng-Meng and Zhu, Qi and Cheng, Xin-Ran and Hou, Chao and Chen, Xin and Wang, Fang and Xu, Chuan-Hui and Li, Chao and Xie, Shuai-Shuai and Wei, Jie and Zhang, Dan-Feng and Zhang, Xin-Ru and Wang, Zhi-Juan and Dong, Yu-Hang and Zhu, Sai and Peng, Li-Jin and Li, Xiang-Yu and Chen, Hai-Yong and Xu, Tao and Jin, Juan and Chen, Fei Xavier and Meng, Xiao-Ming},
title = {NAT10 exacerbates acute renal inflammation by enhancing N4-acetylcytidine modification of the CCL2/CXCL1 axis},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
volume = {122},
number = {17},
doi = {10.1073/pnas.2418409122}
}
EUVIMED